Human immunodeficiency virus type 1 Gag-Pol-Nef polyprotein and Envelope glycoprotein (HIV-1 Gag-Pol-Nef and Env)

The HIV-1 Gag-Pol-Nef polyprotein and Envelope (Env) glycoprotein represent a comprehensive set of antigenic targets used in the development of therapeutic and prophylactic vaccines against HIV-1 (PubMed: 28416512). Gag provides structural proteins like the capsid and matrix, while Pol encodes essential enzymes including reverse transcriptase, integrase, and protease, which are vital for the viral life cycle (UniProt: P04585). Nef is an accessory protein that facilitates immune evasion by downregulating host cell surface receptors, and Env is the surface glycoprotein responsible for viral attachment and entry into host cells (PubMed: 11134021). By targeting these proteins simultaneously, researchers aim to elicit a broad and robust immune response, involving both neutralizing antibodies against Env and cytotoxic T-lymphocyte (CTL) responses against the more conserved internal proteins like Gag and Pol (PubMed: 30206177). This multi-antigen approach is designed to overcome the high genetic diversity and rapid mutation rate of HIV-1, potentially leading to better control of viral replication or prevention of infection. Clinical candidates utilizing these targets, such as Pennvax-GP, often employ DNA plasmids or viral vectors to deliver the genetic sequences to host cells for endogenous expression and presentation to the immune system (ClinicalTrials.gov: NCT02041273).

Other names

HIV-1 multi-antigen constructGag-Pol-Nef-EnvHIV-1 polyproteinsHIV-1 antigenic targets

Induction of broad-spectrum cellular and humoral immune responses against multiple essential viral proteins to inhibit HIV-1 replication and entry.